MC
BIS icon

Moors & Cabot’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Moors & Cabot’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-925
Closed -$213K – 528
2015
Q4 		$213K Buy
+925
New +$238K 0.04% 430

Other funds holding BIS

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Moors & Cabot's BIS Position: Q1 2016 in Review

Moors & Cabot sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2016, closing a stake of 925 shares — an estimated $213K sold.

Moors & Cabot first reported a position in BIS in Q4 2015 and held it in 1 quarter. The position peaked at $213K in Q4 2015. 14 funds tracked by Wall St. Rank hold BIS as of Q1 2016.

  • Moors & Cabot reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2016 after selling out during the quarter.
  • Moors & Cabot sold 925 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2016, an estimated $213K.
  • Moors & Cabot first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2015 and held it in 1 quarter.
  • Moors & Cabot's ProShares UltraShort NASDAQ Biotechnology position peaked at $213K in Q4 2015.
  • 14 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2016.

Based on Moors & Cabot's 13F filing for Q1 2016, filed 10 May 2016.